Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Mitochondriotoxic compounds for cancer therapy

Abstract

One of the hallmarks of cancer cells is their increased resistance to apoptosis induction. Alterations in many apoptosis regulators belonging to the intrinsic pathway confer emerging neoplastic cells with a selective growth advantage in the hostile tumor microenvironment. The realization that those same defects contribute to resistance to radiation and chemotherapeutic agents have prompted the unrelenting search for mitochondria-targeted compounds for the treatment of cancer. Mitochondria play a central role in the process of cell death. They serve as integrators of upstream effector mechanisms. Most importantly, mitochondrial outer membrane permeabilization becomes a commitment point during cell death. Thus, strategies aimed at directly triggering this event by either blocking the activity of antiapoptotic factors or by interfering with vital mitochondrial functions may help to overcome resistance to standard cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Anderson WM, Patheja HS, Delinck DL, Baldwin WW, Smiley ST, Chen LB . (1989). Biochem Int 19: 673–685.

  • Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C et al. (2002). FEBS Lett 532: 256–260.

  • Beinlich A, Strohmeier R, Kaufmann M, Kuhl H . (2000). Biochem Pharmacol 60: 397–402.

  • Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D et al. (2001). Oncogene 20: 7579–7587.

  • Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S et al. (1990). Mol Pharmacol 37: 840–847.

  • Bernardi P, Scorrano L, Colonna R, Petronilli V, Di Lisa F . (1999). Eur J Biochem 264: 687–701.

  • Borner C . (2003). Mol Immunol 39: 615–647.

  • Boveris A, Chance B . (1973). Biochem J 134: 707–716.

  • Brewis ND, Phelan A, Normand N, Choolun E, O'Hare P . (2003). Mol Ther 7: 262–270.

  • Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J et al. (2000). Clin Cancer Res 6: 42–49.

  • Bulet P, Stocklin R, Menin L . (2004). Immunol Rev 198: 169–184.

  • Chahboune N, Barrachina I, Royo I, Romero V, Saez J, Tormo JR et al. (2006). Bioorg Med Chem 14: 1089–1094.

  • Chen LB . (1988). Annu Rev Cell Biol 4: 155–181.

  • Chernyak BV, Bernardi P . (1996). Eur J Biochem 238: 623–630.

  • Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y et al. (2005). J Bioenerg Biomembr 37: 307–317.

  • Chiba Y, Kubota T, Watanabe M, Matsuzaki SW, Otani Y, Teramoto T et al. (1998). Anticancer Res 18: 1047–1052.

  • Clapham DE . (1995). Cell 80: 259–268.

  • Cory S, Adams JM . (2002). Nat Rev Cancer 2: 647–656.

  • Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N et al. (2000). Oncogene 19: 307–314.

  • Csordas G, Madesh M, Antonsson B, Hajnoczky G . (2002). EMBO J 21: 2198–2206.

  • Dang CV, Semenza GL . (1999). Trends Biochem Sci 24: 68–72.

  • Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A et al. (2002). Cancer Res 62: 1388–1393.

  • Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. (2001). Nat Cell Biol 3: 173–182.

  • Dharap SS, Minko T . (2003). Pharm Res 20: 889–896.

  • Dolce V, Scarcia P, Iacopetta D, Palmieri F . (2005). FEBS Lett 579: 633–637.

  • Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S et al. (2003). Cancer Cell 3: 497–509.

  • Eiznhamer DA, Xu ZQ . (2004). IDrugs 7: 359–373.

  • Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD et al. (1999). Nat Med 5: 1032–1038.

  • Ellerby HM, Martin SJ, Ellerby LM, Naiem SS, Rabizadeh S, Salvesen GS et al. (1997). J Neurosci 17: 6165–6178.

  • Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y et al. (2001). J Med Chem 44: 4313–4324.

  • Epand RM, Shai Y, Segrest JP, Anantharamaiah GM . (1995). Biopolymers 37: 319–338.

  • Fantin VR, Berardi MJ, Babbe H, Michelman MV, Manning CM, Leder P . (2005). Cancer Res 65: 6891–6900.

  • Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P . (2002). Cancer Cell 2: 29–42.

  • Forte M, Bernardi P . (2005). J Bioenerg Biomembr 37: 121–128.

  • Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME et al. (1998). J Biol Chem 273: 33942–33948.

  • Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL . (2002). Cancer Res 62: 3909–3913.

  • Goldsmith KC, Hogarty MD . (2005). Cancer Lett 228: 133–141.

  • Gonzalez-Polo RA, Carvalho G, Braun T, Decaudin D, Fabre C, Larochette N et al. (2005). Oncogene 24: 7503–7513.

  • Green DR, Reed JC . (1998). Science 281: 1309–1312.

  • Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM . (2001). Cancer Chemother Pharmacol 48: 169–176.

  • Halestrap AP, Brenner C . (2003). Curr Med Chem 10: 1507–1525.

  • Hanada M, Aime-Sempe C, Sato T, Reed JC . (1995). J Biol Chem 270: 11962–11969.

  • Hsu CA, Rishi AK, Su-Li X, Gerald TM, Dawson MI, Schiffer C et al. (1997). Blood 89: 4470–4479.

  • Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W . (2000). Nature 407: 390–395.

  • Jameel JK, Rao VS, Cawkwell L, Drew PJ . (2004). Breast 13: 452–460.

  • Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M et al. (1998). Nat Med 4: 232–234.

  • Javadpour MM, Juban MM, Lo WC, Bishop SM, Alberty JB, Cowell SM et al. (1996). J Med Chem 39: 3107–3113.

  • Johnstone RW, Ruefli AA, Lowe SW . (2002). Cell 108: 153–164.

  • Kadenbach B . (2003). Biochim Biophys Acta 1604: 77–94.

  • Kaelin Jr WG . (2005). Nat Rev Cancer 5: 689–698.

  • Kandela IK, Lee W, Indig GL . (2003). Biotech Histochem 78: 157–169.

  • Kang D, Hamasaki N . (2005). Curr Med Chem 12: 429–441.

  • Katz Y, Ben-Baruch G, Kloog Y, Menczer J, Gavish M . (1990). Clin Sci (London) 78: 155–158.

  • Kirkinezos IG, Moraes CT . (2001). Semin Cell Dev Biol 12: 449–457.

  • Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M . (2003). J Med Chem 46: 4259–4264.

  • Kitada S, Pedersen IM, Schimmer AD, Reed JC . (2002). Oncogene 21: 3459–3474.

  • Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W . (2004). Nat Med 10: 625–632.

  • Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D et al. (2002). Br J Haematol 118: 521–534.

  • Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH . (2000). Cell Death Differ 7: 1166–1173.

  • Kroemer G . (2002). Biochimie 84: 103–104.

  • Kroemer G, Dallaporta B, Resche-Rigon M . (1998). Annu Rev Physiol 60: 619–642.

  • Kroemer G, de The H . (1999). J Natl Cancer Inst 91: 743–745.

  • Kroemer G, Reed JC . (2000). Nat Med 6: 513–519.

  • Kuwana T, Newmeyer DD . (2003). Curr Opin Cell Biol 15: 691–699.

  • Lacerda SH, Abraham B, Stringfellow TC, Indig GL . (2005). Photochem Photobiol 81: 1430–1438.

  • Linden M, Gellerfors P, Nelson BD . (1982). FEBS Lett 141: 189–192.

  • Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ . (2001). Biochemistry 40: 5542–5547.

  • Lo S, Tolner B, Taanman JW, Cooper JM, Gu M, Hartley JA et al. (2005). Int J Oncol 27: 337–344.

  • Maaser K, Hopfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP et al. (2001). Br J Cancer 85: 1771–1780.

  • Majima E, Ikawa K, Takeda M, Hashimoto M, Shinohara Y, Terada H . (1995). J Biol Chem 270: 29548–29554.

  • Majima E, Shinohara Y, Yamaguchi N, Hong YM, Terada H . (1994). Biochemistry 33: 9530–9536.

  • Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P et al. (1999). Cancer Res 59: 6257–6266.

  • McStay GP, Clarke SJ, Halestrap AP . (2002). Biochem J 367: 541–548.

  • Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T et al. (1995). Cancer Res 55: 2691–2695.

  • Miyashita T, Reed JC . (1993). Blood 81: 151–157.

  • Modica-Napolitano JS, Aprille JR . (2001). Adv Drug Deliv Rev 49: 63–70.

  • Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, Chen LB . (1996). Cancer Res 56: 544–550.

  • Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z . (2005). Eur J Nucl Med Mol Imag 32: 836–842.

  • Nass MM, Nass S . (1963). J Cell Biol 19: 593–611.

  • Newmeyer DD, Ferguson-Miller S . (2003). Cell 112: 481–490.

  • Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). Nature 435: 677–681.

  • Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S et al. (2004). Curr Med Chem 11: 1299–1308.

  • Pastorino JG, Hoek JB . (2003). Curr Med Chem 10: 1535–1551.

  • Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH . (2002). Biochim Biophys Acta 1555: 14–20.

  • Pelicano H, Carney D, Huang P . (2004). Drug Resist Updat 7: 97–110.

  • Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, Cramer JA et al. (1999). Ann Oncol 10: 923–927.

  • Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX et al. (1999). Oncogene 18: 2537–2546.

  • Ravagnan L, Roumier T, Kroemer G . (2002). J Cell Physiol 192: 131–137.

  • Reed JC . (1999). J Clin Oncol 17: 2941–2953.

  • Reed JC, Cuddy M, Haldar S, Croce C, Nowell P, Makover D et al. (1990a). Proc Natl Acad Sci USA 87: 3660–3664.

  • Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S et al. (1990b). Cancer Res 50: 6565–6570.

  • Rodic N, Oka M, Hamazaki T, Murawski MR, Jorgensen M, Maatouk DM et al. (2005). Stem Cells 23: 1314–1323.

  • Rolfe DF, Brown GC . (1997). Physiol Rev 77: 731–758.

  • Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I et al. (1996). J Cell Biol 135: 1889–1898.

  • Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA et al. (2002). Dev Cell 2: 55–67.

  • Singh G, Sharkey SM, Moorehead R . (1992). Pharmacol Ther 54: 217–230.

  • Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF . (1999). Oncogene 18: 6641–6646.

  • Smith RA, Porteous CM, Gane AM, Murphy MP . (2003). Proc Natl Acad Sci USA 100: 5407–5412.

  • Stadtman ER . (2001). Ann N Y Acad Sci 928: 22–38.

  • Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, Shepherd EL et al. (1982). Proc Natl Acad Sci USA 79: 5292–5296.

  • Sutter AP, Maaser K, Hopfner M, Barthel B, Grabowski P, Faiss S et al. (2002). Int J Cancer 102: 318–327.

  • Teicher BA, Holden SA, Jacobs JL, Abrams MJ, Jones AG . (1986). Biochem Pharmacol 35: 3365–3369.

  • Trapp S, Horobin RW . (2005). Eur Biophys J 34: 959–966.

  • Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J et al. (2001). Nat Cell Biol 3: 183–191.

  • van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P . (2002). Cell Death Differ 9: 1031–1042.

  • Venturini I, Alho H, Podkletnova I, Corsi L, Rybnikova E, Pellicci R et al. (1999). Life Sci 65: 2223–2231.

  • Vieira HL, Boya P, Cohen I, El Hamel C, Haouzi D, Druillenec S et al. (2002). Oncogene 21: 1963–1977.

  • Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. (2004). Science 305: 1466–1470.

  • Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE . (2005). Blood 106: 3584–3593.

  • Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. (2000a). Proc Natl Acad Sci USA 97: 7124–7129.

  • Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM et al. (2000b). Cancer Res 60: 1498–1502.

  • Weissig V, Cheng SM, D'Souza GG . (2004). Mitochondrion 3: 229–244.

  • Xu L, Yang D, Wang S, Tang W, Liu M, Davis M et al. (2005). Mol Cancer Ther 4: 197–205.

  • Yamada Y, Shinohara Y, Kakudo T, Chaki S, Futaki S, Kamiya H et al. (2005). Int J Pharm 303: 1–7.

  • Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP et al. (2005). J Am Chem Soc 127: 10191–10196.

  • Zamzami N, Larochette N, Kroemer G . (2005). Cell Death Differ 12(Suppl 2): 1478–1480.

  • Zha H, Aime-Sempe C, Sato T, Reed JC . (1996). J Biol Chem 271: 7440–7444.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V R Fantin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fantin, V., Leder, P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25, 4787–4797 (2006). https://doi.org/10.1038/sj.onc.1209599

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209599

Keywords

This article is cited by

Search

Quick links